scholarly journals Does ‘heparin-induced thrombocytopenia’ hit our minds?

2016 ◽  
Vol 03 (03) ◽  
pp. 245-248
Author(s):  
Arun Thangavel ◽  
Shalvi Mahajan ◽  
Amarjyoti Hazarika
Keyword(s):  
Deep Vein Thrombosis ◽  
Side Effects ◽  
Pulmonary Emboli ◽  
Heparin Induced Thrombocytopenia ◽  
Vein Thrombosis ◽  
Prophylactic Dose ◽  
Patients At Risk ◽  
Newer Anticoagulants ◽  
Deep Vein ◽  
Heparin Prophylaxis

AbstractUnfractionated heparin is a widely used drug to prevent deep vein thrombosis and pulmonary emboli in patients at risk. With the advent of newer anticoagulants having lesser side effects, its use has diminished but not out of service. Here, we report a case of deep venous thrombosis, in a patient on prophylactic dose of heparin, which was later found to be a manifestation of heparin-induced thrombocytopenia (HIT). Thrombosis in the presence of heparin prophylaxis should be considered as HIT rather than a failure of anticoagulation.

scholarly journals Deep Vein Thrombosis Caused by Heparin-induced Thrombocytopenia Thrombosis

2013 ◽  
Vol 52 (8) ◽  
pp. 929-929 ◽  
Author(s):  
Yoji Neishi ◽  
Hiroyuki Okura ◽  
Kiyoshi Yoshida
Keyword(s):  
Deep Vein Thrombosis ◽  
Heparin Induced Thrombocytopenia ◽  
Vein Thrombosis ◽  
Deep Vein

scholarly journals Combination oral contraceptives – a practice-guided overview of everyday problems and their solutions

2020 ◽  
pp. 30-32
Author(s):  
DW Wolmarans ◽  
L Brand ◽  
SF Steyn
Keyword(s):  
Deep Vein Thrombosis ◽  
Side Effects ◽  
Adverse Effects ◽  
Oral Contraceptives ◽  
Cardiovascular Events ◽  
Treatment Withdrawal ◽  
Vein Thrombosis ◽  
Withdrawal Of Therapy ◽  
Deep Vein ◽  
Everyday Problems

Combination oral contraceptives (COCs) are some of the most commonly prescribed drugs for women between the ages of 15–451 and while they are accepted to be safe and highly effective, their use is often associated with a number of minor sideeffects. Considering the limited nature of this review, a detailed overview of the complete clinical profile of COCs falls beyond the current scope. Rather, we will focus on the most frequently reported side-effects of COCs that do not necessitate treatment withdrawal. Adverse effects that require immediate withdrawal of therapy are usually related to deep vein thrombosis (DVT) and other cardiovascular events, malignancies or hepatic pathology2 and would require a more in-depth review.

scholarly journals Association between Cancer and Anatomical Site of Venous Thromboembolic Disease

Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 6-6
Author(s):  
David A Froehling ◽  
Damon E. Houghton ◽  
Waldemar E. Wysokinski ◽  
Robert D. McBane ◽  
Danielle Vlazny ◽  
...  
Keyword(s):  
Deep Vein Thrombosis ◽  
Upper Extremity ◽  
Renal Vein ◽  
The Body ◽  
Published Data ◽  
Anatomical Site ◽  
Pulmonary Emboli ◽  
Vein Thrombosis ◽  
Deep Vein ◽  
Active Cancer

Background:There is limited published data on the association between malignancy and the location of venous thromboembolism (VTE) in the body. Aims:Assess the location of VTE in the body in patients with active cancer and compare these results in patients without malignancy. Methods:Consecutive patients enrolled in the Mayo Clinic VTE Registry between March 1, 2013 and November 30, 2019 for acute VTE were followed prospectively. Anatomical site of thrombosis and malignancy status were recorded. Patient outcomes were assessed in person, by mailed questionnaire, or by a scripted phone interview. Active cancer was defined as treatment for malignancy within the last six months or not yet in remission. Results:During the study period there were 2,798 patients with acute VTE (1256 with and 1542 without active cancer). Pulmonary emboli were more common in patients with active cancer compared to patients without cancer (49.5% vs. 39.7%, p<0.001). Upper extremity deep vein thrombosis (11.4 % vs. 7.7%, p<0.001), renal vein thrombi (1.4% vs. 0.2%, p<0.001) and splanchnic vein thrombi (9.3% vs. 6.0%, p=0.001) were all more common in patients with active cancer compared to patients without cancer. Conclusion:Compared to those without malignancy, patients with active cancer were more likely to have pulmonary emboli, upper extremity deep vein thrombosis, renal vein thrombi, and splanchnic vein thrombi. Disclosures No relevant conflicts of interest to declare.

The risk assessment profile score identifies trauma patients at risk for deep vein thrombosis

Surgery ◽  
2000 ◽  
Vol 128 (4) ◽  
pp. 631-640 ◽  
Author(s):  
Michelle M. Gearhart ◽  
Fred A. Luchette ◽  
Mary C. Proctor ◽  
Dave M. Lutomski ◽  
Christine Witsken ◽  
...  
Keyword(s):  
Risk Assessment ◽  
At Risk ◽  
Deep Vein Thrombosis ◽  
Trauma Patients ◽  
Vein Thrombosis ◽  
Profile Score ◽  
Patients At Risk ◽  
Deep Vein

The Role of Stanozolol in the Treatment of the Postphlebitic Syndrome

1981 ◽  
Vol 26 (1_suppl) ◽  
pp. S81-S83 ◽  
Author(s):  
P. E. Jarrett
Keyword(s):  
Deep Vein Thrombosis ◽  
Side Effects ◽  
Fibrinolytic Activity ◽  
Double Blind ◽  
Vein Thrombosis ◽  
Postphlebitic Syndrome ◽  
Deep Vein ◽  
Blind Crossover Study ◽  
Double Blind Crossover Study

The postphlebitic syndrome is a result of previous deep vein thrombosis and presents with oedema, pain, induration, pigmentation and ulceration. Extravascular deposition of fibrin is associated with reduced fibrinolytic activity in these patients. In a double-blind crossover study there was evidence of benefit from stanozolol which enhanced fibrinolytic activity. No side effects of any consequence were noted with a dosage of 5 mg twice per day.

Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia

Blood ◽  
2003 ◽  
Vol 101 (8) ◽  
pp. 3049-3051 ◽  
Author(s):  
Aaron P. Hong ◽  
Deborah J. Cook ◽  
Christopher S. Sigouin ◽  
Theodore E. Warkentin
Keyword(s):  
Deep Vein Thrombosis ◽  
Upper Extremity ◽  
Orthopedic Surgery ◽  
Venous Catheter ◽  
Central Venous Catheters ◽  
Central Venous ◽  
Heparin Induced Thrombocytopenia ◽  
Vein Thrombosis ◽  
Deep Vein ◽  
Limb Deep Vein Thrombosis

Abstract Heparin-induced thrombocytopenia (HIT) is a transient antibody-mediated hypercoagulability state strongly associated with lower-limb deep-vein thrombosis (DVT). Whether HIT is additionally associated with upper-limb DVT—either with or without central venous catheter (CVC) use—is unknown. We therefore studied 260 patients with antibody-positive HIT to determine the influence of CVC use on frequency and localization of upper-extremity DVT in comparison with 2 non-HIT control populations (postoperative orthopedic surgery and intensive-care unit patients). Compared with the control populations, both upper- and lower-extremity DVTs were found to be associated with HIT. Upper-extremity DVTs occurred more frequently in HIT patients with a CVC (14 of 145 [9.7%]) versus none of 115 (0%) patients without a CVC (P = .000 35). All upper-extremity DVTs occurred at the CVC site (right, 12; left, 2; kappa = 1.0; P = .011). We conclude that a localizing vascular injury (CVC use) and a systemic hypercoagulability disorder (HIT) interact to explain upper-extremity DVT complicating HIT.

Sign in / Sign up

Export Citation Format

Share Document